Gram-positive bacterial infections

This study tests a new vaccine called VAX-31 in adults aged 50 and older who have already received a pneumonia vaccine. The goal is to see if VAX-31 is safe and triggers a strong immune response. About 752 participants will receive either VAX-31 or an active comparator vaccine, a…

This study tests a new pneumococcal vaccine (PG4) to see if it is safe and tolerable in adults. About 380 healthy adults will receive either the experimental vaccine, a similar vaccine, a standard vaccine, or a placebo. Participants will be monitored for side effects and give blo…

This early-stage trial tests a new pneumococcal vaccine called PnMAPS30plus in 121 healthy adults aged 50 to 64. Participants receive a single shot of either the new vaccine or an approved one (PCV20) and are monitored for about six months. The goal is to check safety and whether…

This study tests a new vaccine called VAX-31 to protect babies against pneumococcal disease, which can cause pneumonia and meningitis. About 900 healthy infants will receive four doses of VAX-31 or an existing vaccine starting at 2 months old. Researchers will check for side effe…

This phase 2 trial is testing a new pneumococcal vaccine (PG4) in about 605 healthy infants to see if it is safe and triggers a strong immune response. Infants will receive four doses starting at 2 months old, and the new vaccine will be compared to existing vaccines like Prevnar…

This study looks at how effective the Prevnar 20 (PCV20) vaccine is at preventing serious lung infections in people aged 65 and older. Researchers will analyze medical records from over 22 million Medicare beneficiaries, comparing those who got the vaccine to those who did not. T…

This study tests a new vaccine (PCV21) that protects against 21 types of pneumonia-causing bacteria. About 1,700 healthy infants will receive either the new vaccine or an existing one alongside their routine shots. The goal is to see if the new vaccine is safe and helps babies bu…

This study follows women who previously received the GBS-NN/NN2 vaccine during pregnancy to see how long their immune protection lasts. It also tests whether a booster dose given in a new pregnancy is safe and boosts immunity, aiming to protect newborns from group B strep infecti…

This phase 3 study tests whether a new 21-valent pneumococcal vaccine (PCV21) is safe for healthy infants. About 2360 babies will receive either PCV21 or the current Prevnar 20 vaccine at 2, 4, 6, and 12-15 months old. Researchers will monitor for side effects like injection-site…

This study monitors the safety of the PREVENAR 20 vaccine in 1,100 infants aged 2 to 6 months in Japan. Infants receive four doses as part of routine care, and researchers track any side effects. The goal is to ensure the vaccine is safe for widespread use.

This study tests a new vaccine that protects against 20 types of pneumococcal bacteria, which can cause pneumonia and other infections. Around 200 healthy Chinese adults, children, and infants will receive the vaccine to see if it is safe and how well it triggers an immune respon…

This study looks at how well a pneumonia vaccine (PCV20) works in people who have recovered from B-cell lymphoma and were treated with anti-CD20 therapy. Researchers want to see if a single dose or a boosted dose is safer and more effective at preventing pneumococcal infections. …

This study tests a new 21-valent pneumococcal conjugate vaccine (PCV21) in about 1,092 healthy infants and toddlers. The goal is to see if PCV21 is safe and helps the body produce antibodies against pneumococcal bacteria better than the current licensed vaccine. Participants rece…

This study tests an anthrax vaccine called AV7909 in 220 healthy adults aged 18 to 65. The goal is to see how safe it is and how well it triggers the immune system, using two different dosing schedules and booster shots at 6 and 12 months. Participants will be monitored for side …

This Phase 3 study tests whether mixing a new 21-valent pneumococcal vaccine with a licensed 20-valent version is safe and helps build immunity in healthy infants. About 580 babies will receive different combinations of the vaccines at routine checkups. The goal is to see if flex…

This early-stage trial is testing a new vaccine called PCV24, designed to protect children against 24 types of pneumococcal bacteria. The study involves 230 healthy children aged 6 weeks to 17 years and will check for side effects and measure immune response. The vaccine is given…

This phase II trial tests a new 24-valent pneumococcal conjugate vaccine (PCV24) in 992 adults aged 18 and older. The study aims to check the vaccine's safety and how well it triggers an immune response compared to an existing 23-valent vaccine. Participants receive one dose of e…

This study tests a new vaccine designed to prevent Group B Streptococcus (GBS) infections, which can cause serious illness in newborns. About 600 healthy, non-pregnant women aged 18-49 in the US and South Africa will receive either the vaccine or a placebo. Researchers will check…

This study tests a new 21-valent pneumococcal vaccine (PCV21) in healthy infants, toddlers, children, and adolescents who need catch-up vaccination. Around 1,268 participants will receive either PCV21 or the current 20-valent vaccine. Researchers will monitor side effects and mea…

This phase 3 study tests a new vaccine (DTacP) that protects infants from diphtheria, tetanus, and whooping cough. Around 2,900 healthy babies aged 2-3 months will receive the vaccine to check its safety and how well it triggers immunity. The trial compares different schedules an…

This Phase 2 trial is testing a new vaccine called IVT PCV-25 in healthy infants to see if it is safe and triggers a strong immune response. The vaccine targets 25 types of pneumococcal bacteria, which can cause serious illnesses like pneumonia and meningitis. Around 421 babies w…

This study tests whether online training and regular feedback reports can help doctors prescribe fewer antibiotics for common infections like ear infections, strep throat, sinusitis, and pneumonia in children. About 420 children aged 6 months to 12 years are included. The goal is…

This study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…

This study tests whether using personalized dosing (based on drug levels in the blood) for the antibiotic teicoplanin works better than standard dosing for treating bacterial infections. About 74 adults in hospital intensive care or other units will take part. The goal is to see …

This early-stage study tests a new lab-made antibody injection against tetanus in 68 healthy adults aged 18-60. The main goal is to check safety and side effects, not to treat or prevent tetanus directly. Participants receive a single shot and are monitored for several weeks.

This study looks at how a medicine called BAT® works in children who have or may have been exposed to botulism toxin. The medicine is an antitoxin that helps stop the toxin from causing more harm. Researchers will take blood samples from up to 10 children to see if the dose is ri…

This study looks at whether a saliva sample can be used instead of a throat swab to diagnose Group A Strep (strep throat) in children. Throat swabs can be uncomfortable, especially for kids, while collecting saliva is much easier. Researchers will compare saliva testing to standa…

This study tests a lollipop-shaped device called CandyCollect to see if it can detect strep throat in children ages 5-17. Kids suck on the lollipop for a few minutes, and it captures bacteria in special channels. Researchers compare results to standard throat swabs to see if the …

This study tests a new vaccine called VAX-31, which protects against 31 types of pneumonia-causing bacteria. It is given together with the seasonal flu shot to healthy adults aged 50 and older. The goal is to see if giving both vaccines at the same time is safe and works as well …

This study tests whether a specially designed probiotic, Streptococcus salivarius eK12, can prevent repeated strep throat infections in children aged 3 to 10. The probiotic is given as a daily supplement and aims to crowd out the harmful bacteria without antibiotics. Researchers …

This Phase 3 study is testing a new vaccine called VAX-31 in about 4,000 healthy adults aged 50 and older. The goal is to see if VAX-31 provides better immune protection against more strains of pneumococcal bacteria compared to two current vaccines, Prevnar 20 and Capvaxive. Rese…

Multiple myeloma patients are at high risk for serious bacterial infections like pneumonia. This study at National Taiwan University Hospital will give 101 patients either one or two doses of the PCV13 pneumonia vaccine to see which schedule is safer and boosts immunity better. R…

This study looks at how HIV infection and aging impact the body's response to the Prevnar 13 vaccine, which protects against pneumococcal bacteria. Researchers will measure antibody levels in the lungs, nasal passages, and blood of participants aged 21-45 or 55-75, comparing thos…

This study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…

This study screens adults interested in fecal microbiota transplant (FMT) for Clostridium difficile infection. Researchers will collect medical information and run basic health tests to create a database of potential participants. The goal is to make it faster and easier to enrol…

This study tests a computer tool that uses maps and location data to help infection preventionists find and stop hospital-acquired infections faster. About 25 infection prevention staff will use the tool and report how easy it is to use and whether it helps them respond more quic…

This project works to make sure children with common respiratory infections get the right antibiotics for the right amount of time. It involves over 259,000 kids across many clinics. The goal is to learn the best ways to help doctors follow antibiotic guidelines and reduce unnece…

This study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…

This study was designed to track how the immune system recovers after CAR-T cell therapy and to test a pneumococcal vaccine (PCV-21) in these patients. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any participants were…

This study was designed to see if taking activated charcoal could help clear certain blood thinners (rivaroxaban, apixaban) faster in patients needing an urgent procedure. It planned to enroll 140 adults and measure how quickly the drug left their blood. However, the trial was wi…

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…